ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022
A remote speech-based AI system to screen for early Alzheimer's disease via smartphones.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04828122 (A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting), which is not on this map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Diagnostic utility of speech-based biomarkers in mild cognitive impairment: a systematic review and meta-analysis.Age and ageing · 2025Pooled it
- Stage-Wise IoT Solutions for Alzheimer's Disease: A Systematic Review of Detection, Monitoring, and Assistive Technologies.Sensors (Basel, Switzerland) · 2025Pooled it
- Neural Computation-Based Methods for the Early Diagnosis and Prognosis of Alzheimer's Disease Not Using Neuroimaging Biomarkers: A Systematic Review.Journal of Alzheimer's disease : JAD · 2024Pooled it
- AI-Based Measurement Tools for Intrinsic Capacity in Older Adults: Scoping Review.Journal of medical Internet research · 2026Article
- Reliable detection and continuous monitoring of memory dysfunction in mild cognitive impairment and healthy aging through adaptive computational phenotyping.PLOS digital health · 2026Article
- Digital language measures capture episodic memory disruptions in people with human immunodeficiency virus: A machine learning study.The Clinical neuropsychologist · 2026Article
- Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias.Seminars in neurology · 2026Review
- Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.Expert review of neurotherapeutics · 2026Review
- Digital Health Technologies Applied in Patients With Early Cognitive Change: Scoping Review.Journal of medical Internet research · 2025Article
- Evaluating spoken language as a biomarker for automated screening of cognitive impairment.Communications medicine · 2025Article
- Article
- Preclinical detection of Alzheimer's disease pathology using conceptual discrimination abilities.The journal of prevention of Alzheimer's disease · 2025Article
- Data Leakage in Deep Learning for Alzheimer's Disease Diagnosis: A Scoping Review of Methodological Rigor and Performance Inflation.Diagnostics (Basel, Switzerland) · 2025Review
- A Systematic Review of Natural Language Processing Techniques for Early Detection of Cognitive Impairment.Mayo Clinic proceedings. Digital health · 2025Review
- Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review.Journal of medical Internet research · 2025Article
- A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease.NPJ digital medicine · 2025Article
- Alzheimer's disease and other memory disorders in the age of AI: reflection and perspectives on the 120th anniversary of the birth of Dr. John von Neumann.GeroScience · 2025Review
- Artificial Intelligence in Psychiatry: A Review of Biological and Behavioral Data Analyses.Diagnostics (Basel, Switzerland) · 2025Review
- Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer's and related dementias.NPJ dementia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Artificial intelligence (AI) systems leveraging speech and language changes could support timely detection of Alzheimer's disease (AD). Methods: The AMYPRED study (NCT04828122) recruited 133 subjects with an established amyloid beta (Aβ) biomarker (66 Aβ+, 67 Aβ-) and clinical status (71 cognitively unimpaired [CU], 62 mild cognitive impairment [MCI] or mild AD). Daily story recall tasks were administered via smartphones and analyzed with an AI system to predict MCI/mild AD and Aβ positivity. Results: Eighty-six percent of participants (115/133) completed remote assessments. The AI system predicted MCI/mild AD (area under the curve [AUC] = 0.85, ±0.07) but not Aβ (AUC = 0.62 ±0.11) in the full sample, and predicted Aβ in clinical subsamples (MCI/mild AD: AUC = 0.78 ±0.14; CU: AUC = 0.74 ±0.13) on short story variants (immediate recall). Long stories and delayed retellings delivered broadly similar results. Discussion: Speech-based testing offers simple and accessible screening for early-stage AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.